• Learning Objective 1:   Understand the curative nature of hematopoietic stem cell gene therapy with autologous transplant for primary immune deficiencies
  • Learning Objective 2:   Distinguish vector-mediated gene therapy from site-specific gene editing
  • Learning Objective 3:   Identify the benefits and risks of gene therapy versus gene editing

 

Session date: 
02/03/2022 - 12:00pm to 1:00pm CST
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Caroline Kuo, MD